EXPLORE THE DEPTH OF ELIGARD’S FLEXIBLE DOSING

The versatility of three

subcutaneous doses

To meet the needs

of patients and clinical practice^1,2

TAILORED TO YOUR SCHEDULE, AND YOUR PATIENTS’ NEEDS³

CONVENIENT STORAGE AND HANDLING¹

DELIVERED IN THE ELIGARD PRE-CONNECTED SYRINGE SYSTEM¹

ADMINISTRATION GUIDANCE

Tailored to your schedule

and your patients’ needs^1,3

ELIGARD is available in 1, 3 and 6-month doses for subcutaneous injection and a fine needle with low injection volume^1,4

7.5 mg

1-month
formulation

22.5 mg

3-month
formulation

45 mg

6-month
formulation

Longer-lasting formulations provide

flexibility for patients, with up to 6 months of treatment-free management³

Offering multiple injection sites gives
patients greater flexibility vs a single site^*1

Examples of flexible administration options¹

Upper Arm

Abdomen

Upper Buttock

Thigh

*Injection sites comprise locations with adequate amounts of subcutaneous tissue that
do not have excessive pigment, nodules, lesions, or hair and have not recently been used.¹

Convenient storage and handling

READY-TO-GO

You can keep ELIGARD for up to 4 weeks at room temperature (<25°C), so it is ready for use whenever you need it¹

LONGER TERM STORAGE

Store ELIGARD in the refrigerator (2–8°C) in its original packaging. Acclimatise at room temperature for approximately 30 minutes before administration¹

Delivered in the ELIGARD

Pre-Connected Syringe System¹

With the ELIGARD Pre-Connected Syringe
System, there’s no need to connect the syringes.

Simply

click, mix & inject¹

1. CLICK

Grasp the connector button with your fingers and press until you hear a click. The two syringes are now perfectly aligned with each other.

2. MIX

Hold the syringes in a horizontal position and slowly and gently transfer the liquid from syringe A to the powder of syringe B.

Without bending the syringe system, gently and slowly go back and forth for 60 cycles until obtaining a homogeneous and viscous solution.^†

Turn the syringes vertically with syringe B at the bottom. Transfer the entire mix into syringe B.
Slightly lower the plunger of syringe B to prevent product from leaking out.

Hold the connector and unscrew it from syringe B.

Secure the needle with safety shield onto syringe B by turning it clockwise, without overly tightening. Prior to administration, purge any large air bubbles from Syringe B.

Hold the syringes in a horizontal position and slowly and gently transfer the liquid from syringe A to the powder of syringe B.

Without bending the syringe system, gently and slowly go back and forth for 60 cycles until obtaining a homogeneous and viscous solution.†

Turn the syringes vertically with syringe B at the bottom. Transfer the entire mix into syringe B.
Slightly lower the plunger of syringe B to prevent product from leaking out.

Hold the connector and unscrew it from syringe B.

Secure the needle with safety shield onto syringe B by turning it clockwise, without overly tightening. Prior to administration, purge any large air bubbles from Syringe B.

3. INJECT

Select an appropriate injection site and cleanse it with an alcohol swab.

Administer ELIGARD immediately by grabbing the skin around the injection site, inserting the needle at a 90° angle, and slowly injecting the syringe contents until syringe is completely empty.¹

Watch the full ELIGARD

administration video here

94^%

of healthcare
professionals would
highly recommend
Eligard EPSS system⁶

*For Adverse Event reporting and full Product Information including administration instructions, please visit
[URL link to local prescribing information]

†A single cycle represents 1 push of syringe A and 1 push of syringe B. Sixty cycles are performed during mixing

References

ELIGARD SmPC. Latest version.
Sartor O. Eur Urol Suppl. 2006;5:905–910.
Ouzaid I, et al. Progrès en Urologie. 2011;21:866–87
Center for Drug Evaluation and Research. ELIGARD 45 mg Injection Suspension Approval Package. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/021731s000_Eligard_AdminCorres.pdf. (Last Accessed: July 2025).
Schulman C. BJU Int. 2007;100 (Suppl. 1):6–11
Fortgeschrittenes Prostatakarzinom: Neues Spritzensystem vereinfacht die hoch wirksame ADT mit Leuprorelin-Gel-Implantat.

This website is intended for healthcare professionals only. ELIGARD (leuprorelin acetate) is indicated for the treatment of hormone dependent advanced prostate cancer and for the treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy.¹

The versatility of three

subcutaneous doses

To meet the needs

of patients and clinical practice1,2

TAILORED TO YOUR SCHEDULE, AND YOUR PATIENTS’ NEEDS3

CONVENIENT STORAGE AND HANDLING1

DELIVERED IN THE ELIGARD PRE-CONNECTED SYRINGE SYSTEM1